Related Experiment Video
Updated: Mar 15, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Clinical trials for authorized biosimilars in the European Union: a systematic review
Johanna Mielke1, Bernd Jilma2, Franz Koenig3
1Statistical Methodology, Novartis Pharma AG, 4056, Basel, Switzerland.
Aim:
In 2006, Omnitrope (by Sandoz) was the first approved biosimilar in Europe. To date, 21 biosimilars for seven different biologics are on the market. The present study compared the clinical trials undertaken to obtain market authorization.
Methods:
We summarized the findings of a comprehensive review of all clinical trials up to market authorization of approved biosimilars, using the European public assessment reports (EPARs) published by the European Medicines Agency (EMA). The features compared were, among others, the number of patients enrolled, the number of trials, the types of trial design, choice of endpoints and equivalence margins for pharmacokinetic (PK)/pharmacodynamic (PD) and phase III trials.
Results:
The variability between the clinical development strategies is high. Some differences are explainable by the characteristics of the product; if, for example, the PD marker can be assumed to predict the clinical outcome, no efficacy trials might be necessary. However, even for products with the same reference product, the sample size, endpoints and statistical models are not always the same.
Conclusions:
There seems to be flexibility for sponsors regarding the decision as to how best to prove biosimilarity.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence of Drugs: Drugs with Multiple Indications
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

